1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Mar 2024
Admin
News Article

Domain Collabs with Chime for New ANTI-CCR8 Antibody

Domain Therapeutics and Chime Biologics Have Agreed to Collaborate on Manufacturing to Advance a New ANTI-CCR8 Antibody for Cancer

Immunotherapy

Observation

Domain Therapeutics (""Domain""), a clinical-stage biopharmaceutical company specializing in immuno-oncology treatments targeting G Protein-Coupled Receptors (GPCRs), has entered a partnership with Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) in the biologics sector. The collaboration aims to advance Domain's primary Treg depleting anti-CCR8 antibody candidate, DT-7012, through manufacturing services for potential cancer therapeutics.

Agreement Terms

This agreement involves Chime Biologics overseeing stable cell line development (CLD) and manufacturing of the DT-7012 candidate to support clinical trials across strategic regions.
Leveraging Chime Biologics' advanced global modular facility equipped with single-use bioprocessing technology adhering to international cGMP standards, the collaboration seeks to deliver effective therapeutics for cancer patients worldwide.

About DT-7012

DT-7012, a novel anti-CCR8 mAb designed to deplete tumor-infiltrating Tregs, pivotal immunosuppressive cells, has demonstrated promising anti-tumor efficacy as a monotherapy.
Its superiority over other clinical-stage CCR8 antibodies positions it as a potential best-in-class candidate, aiming to pioneer GPCR-targeting immunotherapies.
These therapies strive to activate anti-tumor immunity in patients resistant to conventional treatments.
Phase I clinical trials for solid tumors are anticipated to commence in early 2025, followed by mid-2025 trials for cutaneous T-cell lymphoma (CTCL).

Words from Chime Biologics

Dr. Jimmy Wei, President of Chime Biologics, expressed anticipation for the strategic partnership, emphasizing the synergy between Domain's leading antibody candidate and Chime Biologics' expertise in CLD and manufacturing. He envisions the collaboration contributing significantly to advancing DT-7012's development across various cancers.

Words from Domain Therapeutics

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, conveyed excitement about collaborating with Chime Biologics, recognizing their scientific and manufacturing prowess. He emphasized DT-7012's potential to revolutionize cancer treatment by harnessing the immune system's anti-tumor capabilities. Domain prioritizes precision research and innovation, welcoming partnerships with like-minded organizations dedicated to advancing immuno-oncology.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!